Updated 02:01 GMT, 17 Nov 2026 SPX 7,416.59 -1.92% NDX 27,197.15 -2.67% VIX 22.91 +18.70% GOLD 3,868.50 -0.46% CL 85.14 -3.86% BTC 65,305.22 0.00%
NAS100 27,197 −2.67% S&P 7,417 −1.92% GOLD $3,869 −0.46% BTC $65,305 VIX 22.91 +18.70% latest tape · as of 02:01 UTC
The Screen · Healthcare · Medical Devices

Bioventus Inc

BVS · NASDAQ · USD · Market cap $817M · 940 employees

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.

FAIL · Does not pass the screen
10.66 USD

Price as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price10.66 USD at the 13 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 13 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed13 Nov 2026 (4 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $14.98 to $21.32, base estimate $16.00 (screen dated 2026-11-13).

Current read
Distribution ?
Undervalued · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price10.66 USD
Fair value16.00
Ethical score70.0/100
Value readUndervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-09Read Distribution10.61+0.5% to today Accumulation gives way to Distribution after a 23% slide in 3 weeks
2026-10-18Read Accumulation13.81-22.8% to today Markdown gives way to Accumulation
2026-10-11Read Markdown13.31-19.9% to today ✓Accumulation gives way to Markdown
2026-10-02Read Accumulation13.31-19.9% to today Markup gives way to Accumulation after a 10% rise in 10 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Bioventus Inc holds its Distribution at $10.66. The statistical read favours the sellers, held for 11 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateThe statistical read favours the sellers, held for 11 days
Price at the screen$10.66
Valuation32.46 trailing · 14.66 forward price to earnings
Values screenFAIL · score 70.0
Beta0.65
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 43.00% Below 33% Interest-bearing debt is 43.0% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 26.27% Below 49% Money owed to the company is 26.3% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Bioventus's business is in a permissible area, but its interest-bearing debt is about 43% of the company, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when BVS's ethical verdict changes

Today BVS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 33% discount to our $16.00 fair value, none competitive moat, 6.60% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

14.98Conservative16.00Base case21.32Growth case 10.66Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 33.4% discount to the base estimate.

The Street's Range
14.00Street low 15.00Street average 16.00Street high 10.66Price

Third-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +41% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $16.00, with a range of $14.98 to $21.32, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it stands out

A 7%-growth business trading at just 14.7x forward earnings, with a none competitive moat. That is a 33% discount to our $16.00 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 5 analysts rate it Strong Buy with a $15.00 average target, about 41% above the screened price.

The fundamentals · plain-English read
Forward P/E14.7xexpensive even after accounting for its growth
Trailing P/E32.5xa premium valuation
EPS, trailing0.41
EPS, forward0.91
Revenue growth+6.6%slow but positive growth
Profit margin4.9%barely profitable
Return on equity16.5%a solid return on shareholder capital
FCF yield7.75%
Debt to equity1.23a meaningful debt load worth watching
Current ratio1.69healthy short-term liquidity
Beta0.65steadier than the market
Short interest, float0.05%
52-week range5.81 - 12.53
MoatNONE
Market cap$817M
Employees940

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

BVS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-16 Distribution $10.66 +0.5% Entry 18

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15.

2026-11-09 Distribution · changed $10.61 -20.4% Entry 17

The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. Since the last review it its composite score rose.

2026-11-02 Accumulation $13.32 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation $13.32 -9.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation $14.65 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Accumulation $14.65 +0.0% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Accumulation $14.65 +6.1% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Accumulation $13.81 +0.0% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Accumulation $13.81 +0.0% Entry 10

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Accumulation $13.81 +0.0% Entry 9

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (5 analysts) rates it none, with a mean price target of $15.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Related Securities · Others in BVS's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $10.19 -10.8% · $892 -10.8%
2 months $9.06 +0.3% · $1,003 +0.3%
3 months $8.60 +5.7% · $1,057 +5.7%
6 months $7.42 +22.5% · $1,225 +22.5%
1 year $6.86 +32.5% · $1,325 +32.5%
2 years $6.47 +40.5% · $1,405 +40.5%
3 years $2.71 +235.4% · $3,354 +235.4%
5 years $18.42 -50.7% · $494 -50.7%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever BVS does next, these words stay.

Bioventus Inc · BVS · Distribution · $10.66
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.